STOCK TITAN
  1. Home
  2. Sec-filings
  3. SCTX
  4. [8-K] Scribe Therapeutics, Inc. Reports Material Event

Scribe Therapeutics Q2 loss, raises $155M

Scribe Therapeutics combined a pipeline-advancing Phase 1 start and CIRM grants with IPO proceeds it expects to extend its funding runway into the first half of 2029.

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Scribe Therapeutics, Inc. (SCTX) reported second quarter 2026 results and highlighted major strategic milestones, including initiation of a first-in-human Phase 1 trial of lead LDL-C lowering candidate STX-1150 and completion of an upsized IPO plus a concurrent private placement to Sanofi.

Collaboration revenue for the quarter was $1.9 million, down from $4.9 million a year earlier, while research and development expenses fell to $8.8 million from $13.9 million. Net loss narrowed to $6.5 million, or $2.62 per share, compared with a $9.9 million loss, or $4.08 per share, in the prior-year period. Cash, cash equivalents and marketable securities were $43.0 million as of June 30, 2026.

The company raised approximately $155.5 million in aggregate gross proceeds from its July 2026 IPO and the Sanofi private placement and expects that, together with existing cash and investments, this will fund operations into the first half of 2029. Scribe also secured more than $25 million in non-dilutive grants from CIRM to advance cardiometabolic programs STX-1200 and STX-1400 toward potential clinical entry as early as 2027.

Positive

  • Raised approximately $155.5 million in gross proceeds from an upsized IPO, full underwriter option exercise, and a concurrent Sanofi private placement, and expects its cash plus these proceeds to fund operations into the first half of 2029.
  • Secured more than $25 million in non-dilutive CIRM grants to advance cardiometabolic gene editing programs STX-1200 and STX-1400 toward potential clinical entry as early as 2027, while initiating the first-in-human Phase 1 trial of lead asset STX-1150.

Negative

  • Collaboration revenue declined to $1.9 million for the quarter ended June 30, 2026, from $4.9 million in the prior-year period, reflecting lower reimbursable R&D activities and reduced revenue recognition under collaboration arrangements.

Filing Explained

The furnished release was not filed under Section 18; June 30 liabilities were $102,417 thousand and stockholders’ deficit was ($164,846 thousand).

The September 2, 2026 Form 8-K reports Scribe’s quarter-ended-June-30 financial results under Item 2.02; Form 8-Ks report specified material events. The disclosure’s structural consequence is procedural: the results release was furnished rather than treated as filed for Section 18 liability.

The filing states that the Item 2.02 information and Exhibit 99.1 are not incorporated by reference into another filing unless expressly stated. This describes the release’s filing status, not a change to the company’s capital structure.

The June 30, 2026 balance sheet reported $102,417 thousand of total liabilities and total stockholders’ deficit of ($164,846 thousand).

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Collaboration revenue Q2 2026 $1.9 million Three months ended June 30, 2026; prior-year period was $4.9 million
Research and development expenses Q2 2026 $8.8 million Three months ended June 30, 2026; down from $13.9 million in 2025
General and administrative expenses Q2 2026 $2.5 million Three months ended June 30, 2026; slightly below $2.6 million in 2025
Net loss Q2 2026 $6.5 million Three months ended June 30, 2026; improved from $9.9 million in prior year
Cash, cash equivalents and marketable securities $43.0 million As of June 30, 2026; down from $58.0 million at December 31, 2025
IPO and private placement gross proceeds $155.5 million Aggregate gross proceeds from IPO, underwriters’ option exercise, and Sanofi private placement
CIRM grants for STX-1200 and STX-1400 $25.7 million Combined non-dilutive grants to advance cardiometabolic programs toward clinical entry
Total liabilities June 30, 2026 $102.4 million Total liabilities as of June 30, 2026; compared with $101.3 million at December 31, 2025
epigenetic silencing medical
"a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting"
in vivo CRISPR-based medical
"a liver-targeted, in vivo CRISPR-based epigenetic silencing therapy that represses PCSK9"
atherosclerotic cardiovascular disease medical
"three major lipid drivers of atherosclerotic cardiovascular disease: LDL-C, Lp(a), and"
Atherosclerotic cardiovascular disease is the chronic narrowing and hardening of arteries caused by buildup of fatty plaques, like pipes gradually clogged by residue, which reduces blood flow to the heart, brain and other organs. It matters to investors because it is a leading driver of demand for drugs, medical devices, diagnostics and long‑term care—and outcomes from clinical trials, approvals or changes in treatment guidelines can quickly affect the market value of companies serving this large, costly area of medicine.
lipoprotein(a) medical
"STX-1200 is designed to lower lipoprotein(a) (Lp(a)) in patients with genetically elevated"
Lipoprotein(a) is a blood particle that carries cholesterol and has an extra protein tag, making it more likely than ordinary cholesterol to promote plaque build-up in arteries; levels are largely inherited and vary little with diet. Investors care because high levels are a clear marker of heart disease risk, driving demand for diagnostics, specialized drugs and regulatory attention—factors that can affect valuations and future sales for companies developing tests or treatments.
Convertible Note financial
"Change in fair value of Convertible Note"
A convertible note is a type of loan that a company gets from investors, which can later be turned into company shares instead of being paid back in cash. It matters because it helps startups raise money quickly without setting a fixed value for the company right away, making it easier to grow and attract investors.
non-human primates medical
"In non-human primates (NHPs), a single administration of an STX-1150 ELXR prototype"
Non-human primates are members of the primate family other than people — such as monkeys and apes — that are used in biomedical research because their biology is closer to humans than rodents. For investors, results from studies in these animals can strongly influence a drug or vaccine’s safety profile, development timeline, regulatory chances and costs, acting like a high-fidelity dress rehearsal before human clinical trials.
Collaboration revenue Q2 2026 $1.9 million $4.9 million in Q2 2025
Research and development expenses Q2 2026 $8.8 million $13.9 million in Q2 2025
General and administrative expenses Q2 2026 $2.5 million $2.6 million in Q2 2025
Net loss Q2 2026 $6.5 million $9.9 million in Q2 2025
Cash, cash equivalents and investments $43.0 million $58.0 million at December 31, 2025
Guidance

The company expects its existing cash, cash equivalents and investments, together with net proceeds from the July 2026 IPO and concurrent private placement, to fund operating expenses and capital expenditure requirements into the first half of 2029.

FAQ

What were Scribe Therapeutics (SCTX) revenues in the second quarter of 2026?
Collaboration revenue for Scribe Therapeutics in the quarter ended June 30, 2026 was $1.9 million, compared with $4.9 million in the same quarter of 2025, primarily due to lower reimbursable research and development activities and reduced revenue recognition under collaboration agreements.

What net loss did Scribe Therapeutics (SCTX) report for Q2 2026?
Scribe Therapeutics reported a net loss of $6.5 million, or $2.62 per basic and diluted share, for the three months ended June 30, 2026. This compares with a net loss of $9.9 million, or $4.08 per share, for the same period in 2025.

How much cash does Scribe Therapeutics (SCTX) have and what is its runway outlook?
As of June 30, 2026, Scribe Therapeutics had $43.0 million in cash, cash equivalents, and marketable securities. Together with approximately $140.6 million in net proceeds from its July 2026 IPO and private placement, the company expects funding into the first half of 2029.

What major financing did Scribe Therapeutics (SCTX) complete in 2026?
Scribe Therapeutics completed an upsized initial public offering priced at $15.00 per share, including full exercise of the underwriters’ option, and a concurrent private placement to Sanofi. These transactions generated approximately $155.5 million in aggregate gross proceeds.

What clinical progress did Scribe Therapeutics (SCTX) report for STX-1150?
Scribe Therapeutics initiated a first-in-human Phase 1 trial in Australia for STX-1150, an in vivo CRISPR-based epigenetic silencing therapy targeting PCSK9 for LDL-C lowering. Initial clinical data from the single ascending dose portion are anticipated in the first half of 2027.

What non-dilutive funding did Scribe Therapeutics (SCTX) receive from CIRM?
Scribe Therapeutics was awarded approximately $25.7 million in combined non-dilutive grants from CIRM, including $12.7 million to advance STX-1200 for Lp(a) lowering and $13.0 million to advance STX-1400 for triglyceride lowering toward potential clinical entry as early as 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000185392100018539212026-09-022026-09-02

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 02, 2026

 

 

Scribe Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-43409

82-2157847

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1150 Marina Village Parkway

 

Alameda, California

 

94501

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 510 626-8587

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, $0.001 par value per share

 

SCTX

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

On September 2, 2026, Scribe Therapeutics Inc. (the "Company") announced its financial results for the quarter ended June 30, 2026 and provided a business update. A copy of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit number

Description

99.1

Earnings Press Release Issued by Scribe Therapeutics Inc on September 02, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: September 2, 2026

 

By:

/s/ Benjamin L. Oakes

 

 

 

Benjamin L. Oakes, Ph.D.

 

 

 

Chief Executive Officer

(Principal Executive Officer)

 

 

img260493329_0.gif

Exhibit 99.1

 

 

 

 

 

Scribe Therapeutics Reports Second Quarter 2026 Financial Results

and Recent Corporate Highlights

 

Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering without permanent genetic changes

 

Awarded more than $25 million from the California Institute for Regenerative Medicine (CIRM) to advance both STX-1200 for Lp(a) lowering and STX-1400 for triglyceride lowering toward clinical entry

 

Completed upsized initial public offering, including full exercise of the underwriters’ purchase option, and a concurrent private placement to Sanofi, generating approximately $155.5 million in aggregate gross proceeds

 

Cash, cash equivalents, and marketable securities of $43.0 million as of June 30, 2026, plus approximately $140.6 million of net proceeds raised from the July 2026 IPO and concurrent private placement, provides funding into the first half of 2029

 

ALAMEDA, Calif., September 2, 2026 – Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today reported financial results for the second quarter ended June 30, 2026, and provided recent corporate and pipeline updates.

“The second quarter and the weeks immediately following represented a transformational period for Scribe,” said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics. “We advanced our lead silencing asset STX-1150 into the clinic, secured significant grant support from CIRM to develop our next two cardiometabolic assets, and successfully completed our initial public offering. These achievements position us to execute across a broadly differentiated portfolio of CRISPR genetic medicines designed to address the three major lipid drivers of atherosclerotic cardiovascular disease: LDL-C, Lp(a), and triglycerides. Our purpose-built technologies are uniquely poised to democratize access to the cardioprotective effects of beneficial human genetics. Guided by nature's blueprint for improved cardiovascular health, our aim is to shift the treatment paradigm of heart disease from chronic intervention of symptoms toward durable disease prevention and lifespan extension.”

 

 

 

Pipeline Highlights

STX-1150: In vivo epigenetic silencing therapy for LDL-C lowering

•
Initiated first-in human Phase 1 clinical trial in Australia for Scribe's epigenetic silencing therapy STX-1150
o
STX 1150 utilizes our Epigenetic Long-term X Repressor (ELXR) and is designed as a liver-targeted, in vivo CRISPR-based epigenetic silencing therapy that represses PCSK9, a genetically and clinically validated target for LDL-C lowering, without permanently altering the underlying DNA sequence.
o
The Phase 1 study, initiated in mid-2026, will evaluate the safety, tolerability, and efficacy of STX-1150 in adults with elevated low-density lipoprotein cholesterol (LDL-C) and increased risk of atherosclerotic cardiovascular disease (ASCVD).
•
Presented late-breaking data at the European Atherosclerosis Society (EAS) Congress supporting STX-1150 for persistent LDL-C lowering after a single dose.
o
In non-human primates (NHPs), a single administration of an STX-1150 ELXR prototype demonstrated PCSK9 silencing of up to 90%, leading to LDL-C reductions of up to 68%.
o
A therapeutically relevant dose of 0.75 mg/kg produced durable LDL-C reductions of greater than 50%, sustained for two years, with liver enzyme profiles comparable to saline controls.
o
A toxicology study in NHPs showed no adverse clinical observations.
•
Epigenetic silencing with STX-1150 is designed to address a major limitation of current LDL-C lowering approaches and is positioned to recapitulate the cardioprotective effects of human genetics.
o
Current LDL-C therapies remain limited by adherence and durability: recent studies show 50 to 70% of patients discontinue LDL-C-lowering medicine within one year, increasing heart attack risk, while evidence indicates lifelong and earlier LDL-C lowering can deliver substantially greater ASCVD risk reduction than late or inadequate treatment.
o
STX-1150 is designed to overcome this gap by using ELXR, Scribe’s highly engineered epigenetic silencing technology, to down-regulate PCSK9 transcription and deliver persistent, potent LDL-C reductions for years without permanently altering DNA.
o
STX-1150 aims to mimic the protective cardiovascular profile seen in people with naturally occurring PCSK9 loss-of-function variants, who can have a 28% lower mean LDL-C, with up to 88% lower coronary heart disease risk. By doing so, STX-1150 should help shift LDL-C management from burdensome chronic treatment toward durable, long-term prevention.
•
Clinical data expected in the first half of 2027.
o
Scribe anticipates reporting initial clinical data, including safety, tolerability, and LDL-C lowering activity, from the single ascending dose (SAD) portion of the STX-1150 Phase 1 trial in the first half of 2027.

STX-1200 and STX-1400: Advancing cardiometabolic gene editing programs targeting genetically driven, severely elevated Lp(a) and triglycerides, respectively. Awarded approximately $25.7 million in combined non-dilutive CIRM grants.

•
Awarded $12.7 million for advancing STX-1200 toward clinical entry as early as 2027.
o
STX-1200 targets LPA utilizing X-Editor (XE), Scribe’s highly engineered genetic editing technology. STX-1200 is designed to lower lipoprotein(a) (Lp(a)) in patients with genetically elevated Lp(a) and associated ASCVD risk. In preclinical studies, STX-1200 surrogates achieved greater than 95% Lp(a) reduction in NHPs.
•
Awarded $13.0 million for advancing STX-1400 toward clinical entry as early as 2027.
o
STX-1400 targets APOC3 utilizing XE. STX-1400 is designed to lower triglyceride-rich lipoproteins and address the risk of acute pancreatitis in severe hypertriglyceridemia, including familial chylomicronemia syndrome and multifactorial chylomicronemia

 

 

 

 

syndrome. In preclinical studies, STX-1400 surrogates achieved greater than 75% on-target APOC3 editing in NHPs.

Platform and Scientific Leadership

Published updated findings in bioRxiv, highlighting the ELXR platform's novel enhancements in potency and safety enabling the durable repression of target genes without permanent DNA modification.

•
The publication illustrates a novel framework for engineering context-aware epigenetic therapies.
•
Further demonstrated that these engineering approaches developed molecules that decrease off-targets by up to 10x and increase on-target activity across loci as much as 4x.
•
To the Company's knowledge, this is the first example of an epigenetic therapy with an allosterically gated sequential proofreading mechanism that meaningfully widens the therapeutic window of CRISPR approaches.

Corporate Highlights

•
Nasdaq listing. Common stock began trading on the Nasdaq Global Market on July 24, 2026, under the ticker symbol “SCTX.” Scribe upsized its initial public offering and priced at the high end of the range at $15.00 per share. The Company also completed a concurrent private placement to Sanofi at the IPO price.
•
Approximately $155.5 million in aggregate gross proceeds. Capital raised from the IPO, the full exercise of the underwriters’ option, and the concurrent private placement totaled $155.5 million before underwriting discounts, commissions, and offering expenses.

 

•
Funding into the first half of 2029. Based on Scribe’s current operating plan, the Company believes its existing cash, cash equivalents, and investments, together with net proceeds from the IPO and the concurrent private placement, will be sufficient to fund its operating expenses and capital expenditure requirements into the first half of 2029.

Second Quarter 2026 Financial Results

•
Cash position: Cash, cash equivalents, and marketable securities were $43.0 million as of June 30, 2026, compared with $58.0 million as of December 31, 2025. Cash, cash equivalents, and marketable securities of $43.0 million as of June 30, 2026, plus approximately $140.6 million of net proceeds raised from the July 2026 IPO and concurrent private placement, provides funding into the first half of 2029.
•
Collaboration revenue: Collaboration revenue was $1.9 million for the three months ended June 30, 2026, compared with $4.9 million for the prior year period in 2025. The decrease was primarily attributable to lower reimbursable research and development activities and reduced revenue recognition under the Company's collaboration arrangements.
•
Research and development expenses: Research and development expenses were $8.8 million for the three months ended June 30, 2026, compared with $13.9 million for the prior year period in 2025. The decrease was primarily attributable to lower personnel-related costs and reduced spending on preclinical research programs, partially offset by increased expenditures supporting the advancement of the STX-1150 Phase 1 clinical trial, including clinical and manufacturing activities.

 

 

 

 

•
General and administrative expenses: General and administrative expenses were $2.5 million for the second quarter of 2026, compared with $2.6 million for the second quarter of 2025. The decrease was primarily attributable to lower administrative costs.
•
Net loss: Net loss was $6.5 million, or $2.62 per basic and diluted share, for the three months ended June 30, 2026, compared with a net loss of $9.9 million, or $4.08 per basic and diluted share, for the same period in 2025.

 

 

About Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit www.scribetx.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including statements regarding Scribe’s strategy, business plans and objectives; the therapeutic potential, safety, efficacy, durability, scalability and clinical or commercial prospects of Scribe’s product candidates and technologies; the design, initiation, enrollment, conduct, timing and results of preclinical studies and clinical trials; the timing of clinical data and other anticipated milestones; the advancement of STX-1150, STX-1200, STX-1400 and other programs; the expected use and benefits of CIRM funding; and Scribe’s expected cash runway and financial position are forward-looking statements. The words “aim,” “anticipate,” “believe,” “continue,” “could,” “design,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “seek,” “should,” “target,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those described under the heading “Risk Factors” in Scribe’s filings with the U.S. Securities and Exchange Commission, including its final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, and future reports that Scribe may file with the SEC. Except as required by law, Scribe undertakes no obligation to update any forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events.

 

Investor Contact:

Investor Relations, Scribe Therapeutics

ir@scribetx.com

 

Media Contact:

Thermal for Scribe Therapeutics

media@scribetx.com

 

 

 

 

 

SCRIBE THERAPEUTICS INC.

Statement of Operations

(in thousands, except share and per share data)

(Unaudited)

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Collaboration revenue

 

$

1,918

 

 

$

4,898

 

 

$

4,151

 

 

$

22,023

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

8,823

 

 

 

13,884

 

 

 

20,128

 

 

 

29,876

 

General and administrative

 

 

2,490

 

 

 

2,641

 

 

 

5,844

 

 

 

9,332

 

Total operating expenses

 

 

11,313

 

 

 

16,525

 

 

 

25,972

 

 

 

39,208

 

Loss from operations

 

 

(9,395

)

 

 

(11,627

)

 

 

(21,821

)

 

 

(17,185

)

Interest income and other income (expense), net

 

 

383

 

 

 

880

 

 

 

898

 

 

 

1,944

 

Interest expense

 

 

(276

)

 

 

(598

)

 

 

(875

)

 

 

(1,197

)

Change in fair value of Convertible Note

 

 

3,023

 

 

 

730

 

 

 

(1,585

)

 

 

2,083

 

Net loss before provision for income taxes

 

 

(6,265

)

 

 

(10,615

)

 

 

(23,383

)

 

 

(14,355

)

(Provision for) / benefit from income tax

 

 

(212

)

 

 

712

 

 

 

(441

)

 

 

1,027

 

Net loss

 

$

(6,477

)

 

$

(9,903

)

 

$

(23,824

)

 

$

(13,328

)

 

 

SCRIBE THERAPEUTICS INC.

Selected Balance Sheet Items

(in thousands, except share and per share data)

(Unaudited)

 

 

June 30,

 

 

December 31,

 

 

2026

 

 

2025

 

 

 

(in thousands)

 

Cash, cash equivalents and investments

 

$

43,009

 

 

$

57,963

 

Total Assets

 

 

57,927

 

 

 

78,219

 

Total Liabilities

 

 

102,417

 

 

 

101,282

 

Total stockholders' deficit

 

$

(164,846

)

 

$

(143,419

)

 

 

 

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents

Press Releases

Other Documents